# 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study

> **NCT05955833** · PHASE1 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 6 (estimated)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- HER2-positive Breast Cancer
- Gastric Cancer
- Metastatic Gastric Cancer
- HER2-positive Gastric Cancer

## Interventions

- **DIAGNOSTIC_TEST:** 89Zr-DFO*-trastuzumab PET scan

## Key facts

- **NCT ID:** NCT05955833
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-26
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2023-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05955833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05955833, "89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05955833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*